Literature DB >> 16135396

Short term outcomes of high power (80 W) potassium-titanyl-phosphate laser vaporization of the prostate.

Tugcu Volkan1, Tasci Ali Ihsan, Ordekci Yilmaz, Ozbek Emin, Sahin Selcuk, Kantay Koray, Ozbay Bedi.   

Abstract

PURPOSE: We have evaluated the safety and efficacy of 80 W potassium-titanyl-phosphate (KTP) laser in the treatment of patients with lower urinary system symptoms (LUTS) due to benign prostatic hyperplasia.
MATERIALS AND METHODS: A total of 186 patients with LUTS have been evaluated using the International Prostate Symptom Score (IPSS) and quality of life (QoL) scoring questionnaire. Volume of prostate, post-micturition volume of residual urine (PVR), maximum flow rate (Qmax) and serum prostate specific antigen (PSA) values were determined. Laser vaporization of the prostate with an 80 W KTP was applied to all the patients. IPSS and QoL scores were evaluated on postoperative days 30, 90 and 180. The below values were measured on the postoperative days mentioned respectively: Qmax-15, 30 and 90; PSA-1, 15, 30 and 60; PVR-90.
RESULTS: The results of 186 patients, who underwent KTP laser treatment, have been evaluated. Mean age of the patients was 66+/-8 (47-90). Mean volume of prostates, mean operative time and mean energy delivery were 48.1+/-13.2 ml (26-70), 57+/-17 minutes (10-120) and 105+/-37 kJ (20-350), respectively. Following the procedures, Foley catheters were removed after a mean time of 7.59+/-0.9 hours (6-13). Compared with the preoperative period, IPSS, QoL, PVR and Qmax values decreased significantly during the postoperative period (p<0.01). Mean preoperative PSA value was 2.59+/-0.9 ng/ml (0.28-4). There were statistically significant increases in PSA values on postoperative day 1 (p<0.001). However, on postoperative day 15, PSA values decreased as low as preoperative values. There was moderate dysuria in 55 (30%) patients with a mean duration of 2 months and mild hematuria in 10 (18%) patients with a mean duration of 1 month postoperatively. Urinary tract infection occurred in 12 (6%) patients. None of the patients had fever or required re-catheterization. We observed contracture of the bladder neck in 2 (1%) patients and clot retention in 2 (1%) patients. Urinary incontinence due to operation was not observed.
CONCLUSIONS: KTP laser vaporization of the prostate is a treatment method which can be used in patients at high risk of anesthesia. This procedure is safe and effective in that it quickly relieves bladder outlet obstruction symptoms and has a low rate of postoperative complications. However, long-term follow-up studies are called for in order to ascertain whether the results of this procedure are durable or not.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16135396     DOI: 10.1016/j.eururo.2005.07.013

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  15 in total

Review 1.  Update on photoselective vaporization of the prostate.

Authors:  Petros Sountoulides; Jean J M C H de la Rosette
Journal:  Curr Urol Rep       Date:  2008-03       Impact factor: 3.092

2.  The application of 120-W high-performance system GreenLight laser vaporization of the prostate in high-risk patients.

Authors:  Wei Tao; BoXin Xue; Yachen Zang; ChuanYang Sun; Dongrong Yang; Yuanyuan Zhang; YuXi Shan
Journal:  Lasers Med Sci       Date:  2012-10-04       Impact factor: 3.161

3.  [Benign prostatic syndrome (BPS). Ablative treatments].

Authors:  O Reich; M Seitz; C Gratzke; B Schlenker; A Bachmann; C Stief
Journal:  Urologe A       Date:  2006-06       Impact factor: 0.639

4.  Impact of preoperative haemoglobin concentrations on the efficiency of KTP-laser vaporization of the prostate.

Authors:  Stephan Buse; Christian Gilfrich; Gencay Hatiboglu; Johannes Huber; Jens Bedke; Jesco Pfitzenmaier; Axel Haferkamp; Markus Hohenfellner
Journal:  World J Urol       Date:  2009-01-15       Impact factor: 4.226

5.  Changes in Serum Prostate-Specific Antigen Levels after Potassium-Titanyl-Phosphate (KTP) Laser Vaporization of the Prostate.

Authors:  Myungsun Shim; Taekmin Kwon; Seong Chul Kim; Seong-Heon Ha; Tai Young Ahn
Journal:  Korean J Urol       Date:  2010-02-18

6.  Impact of prostate volume on the efficacy of high-power potassium-titanyl-phosphate photoselective vaporization of the prostate: a retrospective, short-term follow-up study on evaluating feasibility and safety.

Authors:  Ja Hyeon Ku; Soo Woong Kim; Jae-Seung Paick
Journal:  Yonsei Med J       Date:  2010-11       Impact factor: 2.759

7.  Photoselective vaporization of the prostate for the treatment of benign prostatic hyperplasia.

Authors:  Tania Stafinski; Devidas Menon; Kevin Harris; Gary Gray Md; Gian Jhangri
Journal:  Can Urol Assoc J       Date:  2008-04       Impact factor: 1.862

8.  Review of current laser therapies for the treatment of benign prostatic hyperplasia.

Authors:  E Charles Osterberg; Benjamin B Choi
Journal:  Korean J Urol       Date:  2013-06-12

Review 9.  [Benign prostatic hyperplasia (BPH) : Surgical therapy options].

Authors:  O Reich; M Seitz; C Gratzke; B Schlenker; S Walther; C Stief
Journal:  Urologe A       Date:  2010-01       Impact factor: 0.639

10.  Optimal Monitoring of Prostate-Specific Antigen Detects Prostate Cancer at the Localized Stage after Photoselective Vaporization for Benign Prostatic Hyperplasia.

Authors:  Jun Furusawa; Yasushi Yamada; Norihito Soga; Isao Kuromatsu
Journal:  Curr Urol       Date:  2019-05-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.